A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Revakinagene taroretcel (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 25 Sep 2024 Planned End Date changed from 15 Dec 2024 to 15 Dec 2025.
- 25 Sep 2024 Planned primary completion date changed from 15 Aug 2024 to 15 Aug 2025.
- 15 Nov 2022 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.